» Articles » PMID: 15632314

Gene-expression Profiling Reveals Down-regulation of Equilibrative Nucleoside Transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived Cells

Overview
Journal J Biochem
Specialty Biochemistry
Date 2005 Jan 6
PMID 15632314
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

We have investigated the mechanism of resistance of leukemia cells to Ara-C using an in-house cDNA microarray designed for the analysis of leukemia cells. We produced Ara-C-resistant cells from the CCRF-CEM (acute lymphoblastic leukemia) cell line and compared their gene-expression profile with that of wild-type cells. The adenosine deaminase (ADA) gene was highly up-regulated in Ara-C-resistant cells, while equilibrative nucleoside transporter 1 (ENT1) and several cell-cycle-related genes were down-regulated. Of all these genes, ENT1 seemed the most likely to be relevant to Ara-C resistance. To investigate the role of ENT1 in Ara-C-resistant cells, we transfected the cells with the gene. ENT1-transfected Ara-C-resistant cells resembled wild-type CCRF-CEM cells more closely than untransfected Ara-C-resistant cells in terms of growth rate, Ara-C-uptake characteristics, and ADA expression levels. The down-regulation of the ENT1 gene is expected to result in nucleotide deficiency in addition to blockage of Ara-C influx. Accordingly, Ara-C-resistant cells showed low growth rates, which were restored by transfection with ENT1. These low growth rates were also correlated with the phosphorylation level of cell-cycle checkpoint kinase 2. In this study we identified down-regulation of ENT1 as the factor responsible for Ara-C resistance, and this knowledge may be used to devise a clinical regimen that will overcome the resistance.

Citing Articles

IFN-stimulated metabolite transporter ENT3 facilitates viral genome release.

Hsieh Y, Tsai T, Huang S, Heng J, Huang Y, Tsai P EMBO Rep. 2023; 24(3):e55286.

PMID: 36652307 PMC: 9986816. DOI: 10.15252/embr.202255286.


Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities.

Kaur T, Weadick B, Mace T, Desai K, Odom H, Govindarajan R Pharmacol Ther. 2022; 240:108300.

PMID: 36283452 PMC: 10290419. DOI: 10.1016/j.pharmthera.2022.108300.


Nucleoside transporter-guided cytarabine-conjugated liposomes for intracellular methotrexate delivery and cooperative choriocarcinoma therapy.

Fei W, Zhao Y, Wu X, Sun D, Yao Y, Wang F J Nanobiotechnology. 2021; 19(1):184.

PMID: 34130695 PMC: 8207694. DOI: 10.1186/s12951-021-00931-3.


Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.

di Francia R, Crisci S, De Monaco A, Cafiero C, Re A, Iaccarino G Cancers (Basel). 2021; 13(5).

PMID: 33669053 PMC: 7956511. DOI: 10.3390/cancers13050966.


Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine.

Visser N, Lourens H, Huls G, Bremer E, Wiersma V Int J Mol Sci. 2021; 22(5).

PMID: 33652766 PMC: 7956277. DOI: 10.3390/ijms22052337.